Context
Cleerly is a U.S. based company whose mission is to create digital care pathways to prevent heart attacks by integrating high-quality clinical science with the latest-generation AI.
Using data-driven solutions, the company provides a comprehensive solution for cardiovascular disease evaluation that improves heart health for patients at risk of heart attacks.
Bryan, Garnier & Co was retained to arrange a Series B financing round that will enable the company to scale-up and expand its commercial and operational capabilities.
Proceeds will also empower Cleerly to leverage its technologies to provide holistic assessment of patients’ cardiovascular system beyond coronary artery disease.
About Cleerly
Founded in 2016 and based in New York City, Cleerly develops a healthcare platform that defines a new standard of care for coronary artery disease. Using value-based precision diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging.
The company's platform adopts an AI-driven approach that supports the understanding of plaques and offers comprehensive quantification and characterization of plaque buildup in the heart arteries. This enables healthcare providers to drastically improve the identification of at-risk patients for early treatment and prevention of heart attacks in a cost-effective manner.
Bryan, Garnier & Co acts as Sole Financial Advisor to Cleerly on its USD 43 million Series B Fundraising
Bryan, Garnier & Co acted as Sole Financial Advisor to Cleerly on its Series B fundraising round.
The financing, which was led by Vensana Capital with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures, and existing investors, brings Cleerly’s total funding to $54 million.
The process targeted more than 200 life sciences VC investors across U.S., Europe, and Asia. Approximately 60 virtual meetings were held during the pandemic and >20 investors conducted extensive due diligence.
Several term sheets were received as part of a highly competitive process and Bryan Garnier helped negotiate the best financial and structural terms for the company.
Bryan, Garnier & Co’s deep healthcare industry expertise, combined with 20 years of experience in arranging financing for growth-stage businesses, enabled Cleerly to secure an optimal transaction to drive its commercial scale-up and operational development.
Share